Sunitinib (SU11248) it is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vegf receptors 1, 2, 3, and pdgfra and pdgfrb. The gene discussed is NTRK1; the disease is neoplasm.